Clinical evidence demonstrates the efficacy of loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma, suggesting its importance in treatment options.
Key Points
To evaluate the clinical evidence and practical guidance for using loncastuximab tesirine in R/R DLBCL.
Overview of clinical evidence for loncastuximab tesirine
Description of three clinical cases
Discussed management and safety during treatment
Explored use as a bridge to allogeneic stem cell transplantation
Efficacy of loncastuximab tesirine illustrated in clinical cases
Demonstrated safety profile
Highlighted its role in therapy sequencing for R/R DLBCL